All In Biotech

Drug Trial Radar · NCT05754853

A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer

An Open-label, Randomized, Multi-center, Phase III Clinical Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Urothelial Cancer Previously Treated With Platinum-based Chemotherapy and PD-1/PD-L1 Inhibitors

Last checked: Nov 19, 2026Latest source record: Apr 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 290 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

290

Planned (sponsor's estimate)

Start

Apr 6, 2023

Primary completion

Oct 2025

Study completion Jan 2027

Sponsor

Lead sponsor
Shanghai Miracogen Inc.Industry
Sponsor type
Industry
First posted
Mar 6, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to compare the overall survival (OS) and progression-free survival (PFS) between MRG002 and investigator selected chemotherapy in patients with HER2-positive unresectable locally advanced or metastatic urothelial cancer previously treated with platinum-based chemotherapy and PD-1/PD-L1 inhibitors.

Conditions

  • Advanced or Metastatic Urothelium Cancer

Interventions

  • MRG002Drug

    Administrated intravenously

  • Docetaxel InjectionDrug

    Administrated intravenously

  • Paclitaxel InjectionDrug

    Administrated intravenously

  • Gemcitabine Hydrochloride for InjectionDrug

    Administrated intravenously

  • Pemetrexed Disodium InjectionDrug

    Administrated intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: Baseline to study completion (up to 36 months)
  2. Progression-Free Survival (PFS) by Independent Review Committee (IRC)Time frame: Baseline to study completion (up to 36 months)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.